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The action of the collagen binding receptor tyrosine kinase (RTK)
discoidin domain receptor 2 (DDR2) in both tumor and tumor
stromal cells has been established as critical for breast cancer
metastasis. Small molecule inhibitors that target the extracellular
domain of RTKs are rare, as they have classically been regarded as
too small to block binding with large polypeptide ligands. Here,
we report the identification and characterization of a selective,
extracellularly acting small molecule inhibitor (WRG-28) of DDR2
that uniquely inhibits receptor–ligand interactions via allosteric
modulation of the receptor. By targeting DDR2, WRG-28 inhibits
tumor invasion and migration, as well as tumor-supporting roles of
the stroma, and inhibits metastatic breast tumor cell colonization in
the lungs. These findings represent an approach to inhibiting tumor–
stromal interactions and support the development of allosteric
inhibitors of DDR2, such as WRG-28, as a promising approach to
antimetastasis treatment.
DDR2 | metastasis | allosteric inhibition
With advances in the management of local breast cancers,metastatic spread is now responsible for greater than 90%
of breast cancer-related deaths. Cross-talk between tumor cells
and their surrounding cellular, chemical, and physical microen-
vironment is now appreciated to be critical for breast tumor
development, metastasis, and response to treatment (1). In
breast tumors, these stromal components differ from their nor-
mal tissue counterparts in composition, architecture, and func-
tion. For example, increased collagen deposition contributes to
breast density, and women with dense breasts have an increased
risk for developing aggressive breast cancers (2). Moreover, ex-
cessive collagen deposition, altered collagen fiber organization,
and the resulting alterations in mechanical properties of the
breast tumor stroma are all correlated with more aggressive
disease and poor outcome (3). Therefore, a proposed reason for
the limited success of current therapies in the metastatic setting
is the lack of modulating both tumor cells and the tumor mi-
croenvironment (4).
Receptor tyrosine kinases (RTKs) are well appreciated ther-
apeutic targets for the treatment of cancer (5). The ligands that
activate these receptors are typically polypeptide growth factors
or cytokines, with one distinct exception—the discoidin domain
receptor (DDR) family. Their ligand is fibrillar collagen, a
structural protein whose expression is increased in the stroma of
aggressive breast cancers (6, 7). DDRs are also unique in that
their activation and inactivation kinetics are slow, and they exist
as preformed dimers on the cell surface in the absence of ligands.
As a result, precisely how DDR activation is regulated remains
unknown. Recent human clinical data and preclinical mouse
genetic models have established DDR2 as a potential thera-
peutic target for the metastasis of breast cancer (8), as well as
many other epithelial-derived carcinomas (9–14).
In breast tumor cells, the action of DDR2 sustains their in-
vasive and migratory capacity by sustaining the cellular level and
activity of SNAIL1 in an ERK-dependent manner (9, 15). In the
breast tumor stroma, the action of DDR2 in cancer-associated
fibroblasts (CAFs) remodels the tumor stromal extracellular
matrix (ECM) leading to a proinvasive collagen organization (8),
as well as controlling CAF-secreted factors that further enhance
tumor collective invasion (8). Together, these data suggest that
DDR2 could be an important target for the development of
inhibitors capable of modulating both the tumor cell and
microenvironment, concurrently.
Most drugs targeting RTKs are of two classes. The first is
receptor antibodies that block ligand binding, receptor dimer-
ization, or receptor internalization (16, 17). The second is small
molecule tyrosine kinase inhibitors (TKIs) that interact with the
intracellular kinase domain (18). While TKIs inhibiting DDR2
have been identified, these compounds exhibit only a preference
for DDR2 inhibition (19). Effective and lasting use of traditional
TKI strategies have been hampered by the emergence of drug
resistance (20), and acquired gatekeeper mutations in DDR2
treated with TKIs have already been reported (21). Therefore,
development of inhibitors of DDR2 with alternative mechanisms
of action could be highly advantageous.
Only recently has a small molecule allosteric regulator that
targets the extracellular domain (ECD) of an RTK been de-
scribed (22, 23). Allosteric or nonclassical small molecule in-
hibitors of RTKs offer significant therapeutic advantages (24,
25). Here, we describe the identification and characterization of
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an extracellularly acting small molecule allosteric inhibitor of
DDR2 that functions to disrupt DDR2 receptor–collagen
ligand interaction.
Results
Identification of a Selective, Small Molecule Inhibitor of the DDR2
ECD. To identify nonclassical inhibitors of DDR2, we adapted a
DDR2 ECD binding assay (26) using plates coated with a
DDR2-selective, high affinity collagen II-derived peptide (27,
28) (SI Appendix, Fig. S1A). A previous in vitro screen for
DDR2 inhibitors identified the natural antibiotic, actinomycin
D, as a weak inhibitor (29). By screening in the ECD binding
assay, we were able to establish that actinomycin D inhibits
DDR2 by acting on the extracelluar domain of the protein (Fig.
1A), as the kinase domain is absent in this assay. Due to its low
potency and high toxicity profile (30), actinomycin D would not
be considered a clinically suitable inhibitor of DDR2. Therefore,
we deconstructed actinomycin D to various component chemical
scaffolds to identify an active portion of the molecule, allowing
for further derivatization to develop lower toxicity, higher
potency inhibitors. The scaffold 7-hydroxy-phenoxazin-3-one
inhibited DDR2 binding with an IC50 of 16 μM (Fig. 1A and SI
Appendix, Fig. S1B). Medicinal chemistry-based optimization was
performed to generate a library of lead compounds (SI Appendix,
Figs. S1B and S2). One of these, WRG-28 (Fig. 1B and SI Ap-
pendix, Fig. S1C), showed moderate potency as an antagonist of
DDR2-ligand binding (IC50 230 ± 75 nM) (Fig. 1A and SI Ap-
pendix, Fig. S1B) and was chosen for further study.
In response to collagen I stimulation, DDR2 is activated (ty-
rosine phosphorylated) and leads to downstream activation of
ERK to stabilize the SNAIL1 protein, thereby regulating cell
migration (9). In HEK293 cells expressing DDR2, WRG-
28 blunted collagen I-mediated DDR2 tyrosine phosphoryla-
tion, ERK activation, and SNAIL1 protein stabilization (IC50
286 ± 124 nM) (Fig. 1 C and D). Normal mammary epithelial
MCF10A cells, which do not express DDR2, were unaffected in
their proliferation or survival (SI Appendix, Fig. S1D) when
treated with WRG-28 (1 μM), demonstrating the absence of
nonspecific toxicity from the inhibitor.
The inhibitory activity of WRG-28 was selective for DDR2.
Collagen I-induced tyrosine phosphorylation of the related DDR1
RTK in HEK293 cells was unaffected by WRG-28 (SI Appendix,
Fig. S1E). Further, using biolayer interferometry (BLI), we ob-
served a dose-dependent association of WRG-28 with DDR2, but
not DDR1 (SI Appendix, Fig. S1 F–H). WRG-28 did not inhibit
collagen binding of α1β1 integrin ECD (SI Appendix, Fig. S1I).
Finally, WRG-28 treatment did not affect phosphorylation of
unrelated RTKs, as determined by RTK signaling arrays (SI Ap-
pendix, Fig. S3 A and B).
In summary, WRG-28 appeared to be a potent and selective
inhibitor of DDR2 ECD binding to collagen in vitro, and col-
lagen I mediated DDR2 activation in cells.
WRG-28 Inhibits DDR2–Collagen Interaction in an Allosteric Manner.
Since no ECD inhibitors of DDR2 have been described, we
sought to determine the mode of inhibition for WRG-28. A
fluorescein-conjugated analog of the DDR2 binding collagen
peptide was used to quantify the amount of substrate bound
to assay plates. Fluorescein conjugation did not alter DDR2
binding to the collagen peptide (SI Appendix, Fig. S3C). In the
range of substrate concentrations examined, there was linear
adsorption of the DDR2 binding collagen peptide that was not
reduced upon washing (SI Appendix, Fig. S3D). Using the
amount of collagen peptide plated as a measure of available li-
gand, increasing concentration of added DDR2 ECD did not
outcompete the inhibitory effects of WRG-28 (Fig. 1E). This
suggested that WRG-28 was not acting as an orthosteric inhibitor
of collagen binding.
Next, we asked whether WRG-28 displaced DDR2 from pre-
bound DDR2 ECD–collagen peptide complexes. After allowing
receptor–ligand complex to reach equilibrium, the complex was
treated with WRG-28. In the absence of inhibitor, there was little
dissociation of DDR2 over 90 min (Fig. 1F). However, in the
presence of WRG-28, there was a dramatic acceleration of
DDR2 dissociation from collagen peptide, in a dose-dependent
manner (Fig. 1F).
Previous reports have shown that for DDR2 ECD to bind
collagen, it must exist as a dimer (26) or possibly higher order
multimer (31). Therefore, we asked whether WRG-28 impaired
or disrupted receptor dimerization or multimerization. To do so,
we made use of a DDR2 ECD protein that covalently dimerized
as a result of a Fc tag added to the C terminus (DDR2-Fc) (32).
In the solid phase binding assay, WRG-28’s capacity to inhibit
covalent DDR2-Fc dimer binding to collagen peptide was
dramatically reduced (SI Appendix, Fig. S3E), suggesting that
inhibition by WRG-28 may require DDR2 dimer or multimer
disruption.
To determine if WRG-28 affected the organization of the
DDR2 ECD in solution, we employed size exclusion chroma-
tography. Consistent with previous reports, the majority existed
as a presumed dimeric complex, while ∼20% of the DDR2 ECD
eluted as a higher molecular mass oligomer, with very little
monomer present (Fig. 1G) (26). A molecular mass calibration
curve for the column was established using standard proteins of
known molecular mass (SI Appendix, Fig. S3G). Monomeric
DDR2 ECD runs at ∼72 kDa on SDS reducing gels. When the
elution volume of the large peak was plotted using calibration
curve for the column, it approximated a molecular mass consis-
tent with a dimeric species (Kav = 0.27,Mr predicted = 154 kDa).
The molecular mass of the smaller peak was estimated to be
approximately double that of the dimer peak (Kav = 0.44, Mr
predicted = 307 kDa), consistent with the molecular mass of an
oligomeric species. When elution fractions were concentrated,
run on a native gel, and compared with the DDR2 ECD protein
solution added to the column, the “oligomeric” peak ran at a
higher size than the dimeric peak (Fig. 1H). The oligomeric and
dimeric peaks were collected, protein concentration normalized,
and subjected to in vitro binding analysis using the solid phase
assay (Fig. 1I). The oligomeric species bound to the collagen
peptide with threefold higher affinity, illustrating the functional
relevance of this higher order species. When the DDR2 ECD
solution was treated with 1 μM WRG-28, the oligomer fraction
was significantly reduced (Fig. 1 G and J). There appeared to be
a corresponding increase in the monomeric state; however, since
the monomer appeared as a shoulder of the dimer peak and was
not well resolved, it could not be accurately quantified (SI Ap-
pendix, Fig. S3F).
In another approach testing whether WRG-28 could disrupt
DDR2 dimers in cells, we performed chemical cross-linking of
HEK293-DDR2 cells with membrane-impermeable BS3. Con-
sistent with previous reports, full-length DDR2 existed as dimers
on the cell surface in the absence of collagen (SI Appendix, Fig.
S3H) (33). When HEK293-DDR2 cells were treated with WRG-
28, we did not detect significant disruption in the amount of cell
surface DDR2 dimerization (SI Appendix, Fig. S3H). This could
be due to the fact that in cells, full-length DDR2 dimerization is
strongly influenced by the transmembrane domain (33). Re-
gardless, WRG-28 was not capable of complete disruption of
full-length DDR2 cell surface dimers.
In summary, these results indicated that WRG-28 inhibitory
activity was not due to ligand-receptor binding site modulation.
Rather, these results are consistent with allosteric regulation of
DDR2–collagen interactions possibly due to impairment in
higher order clustering of the ECD.











Identification of DS-DSL Domain Interface Residues Required for
DDR2–Collagen Binding and Signaling. The extracellular portion
of the DDR proteins consists of three domains—an N-terminal
collagen binding discoidin (DS) domain, a discoidin-like (DSL)
domain, and a short membrane proximal juxtamembrane do-
main. The collagen binding motif in the DS domain is highly
conserved between DDR1 and DDR2 (34). To gain insight into
the structural determinants of DDR2 inhibition by WRG-28,
SWISS-MODEL (35) was used to construct a homology model
of the 3D structure of the DDR2 ECD, using the existing crystal
structure of the DDR1 ECD. This structure and the resulting
model contain the DS and DSL domains but lack the juxta-
membrane domain (Protein Data Bank ID code 4AG4) (36).
WRG-28 in silico docking analysis with AutoDock Vina (37) was
performed against the homology model of DDR2. Of the top
nine WRG-28 binding solutions, five low energy conformations
clustered around a similar site located at the interface of the DS-
DSL domains (Fig. 2A and SI Appendix, Fig. S4 A and B). Such
interface binding can be a common mode of action of allosteric
inhibitors (38, 39), as conformational changes along interfaces
are often needed for proper receptor function (40).
In the lowest energy configuration, several key interactions
were suggested (Fig. 2B). These included polar contacts with
Arg135, Glu247, Thr98, and hydrophobic interactions with
Phe96, Trp187. Residues within the interdomain region have
been shown to make important interdomain contacts in the
Fig. 1. Identification of DDR2 inhibitor and mode of action. (A) Solid-phase binding assay of 25 nM DDR2-His and 500 ng of immobilized ligand. Cinnabarinic
acid (blue), 7-hydroxy-phenoxazin-3-one (red), actinomycin D (green), phenoxazine (purple), WRG-28 (orange). Graph shows mean ± SEM from a repre-
sentative experiment of three independent experiments, three replicates per treatment per experiment. (B) Structure of N-ethyl-4-(((3-oxo-5a,10a-dihydro-3H-
phenoxazin-7-yl)oxy)methyl)benzenesulfonamide (WRG-28). (C) HEK293 cells transfected with DDR2-Flag were added to plates coated with 30 μg/mL col-
lagen I for 4 h in the presence of WRG-28. DDR2 was immunoprecipitated with Flag antibody, and bound products were Western blotted with pTyr mAb
4G10 and reprobed with anti-DDR2 antibody. Densitometric quantification was performed. A representative blot was shown, quantification of five in-
dependent experiments represented as mean ± SEM. (D) HEK293 cells expressing DDR2-Flag were added to plates coated with 30 μg/mL collagen I for 7 h in
the presence or absence of WRG-28. Western blots with the indicated antibodies were performed. Quantification of p-ERK2 and SNAIL1 are indicated on blot.
(E) Twenty-five nanomolar DDR2-His binding in the presence of increasing concentration of collagen peptide and varying concentrations of WRG-28. DMSO
control (blue), 250 nM WRG-28 (red), 500 nM WRG-28 (green), 2 μM WRG-28 (purple). Data are means ± SEM from a representative experiment of three
independent experiments, three replicates per treatment per experiment. (F) Twenty-five nanomolar DDR2 bound to immobilized collagen peptide in solid-
phase binding assay at equilibrium was exposed to a titration of compound. Graph shows dissociation of DDR2 ECD from ligand after exposure to compound
at indicated concentrations for time indicated. DMSO control (blue), 250 nMWRG-28 (red), 500 nMWRG-28 (green). Data are independent time points from a
representative experiment of three independent experiments. (G) Size exclusion chromatography. Representative elution profile of DDR2-His is shown in the
presence or absence of 1 μM WRG-28 on a Superdex 200 Increase 10/300 GL column. Oligomer (O) Kav = 0.27, dimer (D) Kav = 0.44, monomer (M). (H) Native
10% PAGE fraction analysis, followed by silver staining. (I) Protein concentration of dimer or oligomer fractions was normalized and subjected to in vitro binding
assay. Three replicates of each condition were tested, data represented as mean ± SEM. (J) Area under the curve was used to quantify fraction of DDR2 multimer
(oligomer) compared with total DDR2. Three independent runs of each condition were quantified, data represented as mean ± SEM. **P < 0.01.
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crystallized structure of DDR1 (36). As shown, WRG-28 did not
show any inhibitory activity against DDR1 (SI Appendix, Fig.
S1E), despite 53% sequence identity shared between the ECDs
of the two proteins. Among the interface region, two key po-
tential interacting residues in DDR2, Phe96 and Thr98, were not
conserved in DDR1 (DDR1: Leu96 and Ala98, respectively).
Single F96A or T98A point mutations in DDR2 showed no
appreciable effect on DDR2 binding to collagen in vitro,
DDR2 phosphorylation in cells, or inhibition by WRG-28 (SI
Appendix, Fig. S4 C–E, repectively). However, DDR2F96A/T98A
double mutant ECD protein no longer bound to collagen peptide
at concentrations of ligand where binding was saturated for wild-
type DDR2 ECD (Fig. 2C). When DDR2F96A/T98A ECD was
analyzed by size exclusion chromatography, only the presumed
dimer fraction, with virtually no higher order oligomers, was
present (Fig. 2D). This suggested that ECD clustering may be
important for collagen binding in solid phase assays. When
DDR2F96A/T98A was expressed as a full-length receptor in
HEK293 cells, it was present at the cell surface and dimerized
(SI Appendix, Fig. S4 F–H). Despite this, collagen-mediated
DDR2F96A/T98A receptor activation in cells was dramatically re-
duced compared with wild-type receptor (Fig. 2E). In controls,
DDR2 mutants of alternative, lower probability WRG-
28 binding sites (SI Appendix, Fig. S4I) did not affect collagen
peptide binding in vitro, collagen-induced receptor phosphory-
lation in cells, or WRG-28 inhibitory activity (SI Appendix, Fig.
S4 J–M).
As these two residues were not conserved between DDR1 and
DDR2, and WRG-28 is selective for DDR2, we asked whether
we could confer inhibition by WRG-28 upon DDR1 by replacing
Leu96 and Ala98 residues in DDR1 with the key interacting
residues of the DDR2 counterpart (Phe and Thr, respectively).
When a DDR1L96F/A98T mutant was expressed in HEK293 cells
and subjected to treatment with WRG-28, its phosphorylation in
response to collagen was now diminished in the presence of WRG-
28 (Fig. 2F), unlike wild-type DDR1 (SI Appendix, Fig. S1I).
These modeling studies, coupled with in vitro and cell-based
mutagenesis experiments, indicated that the Phe96 and
Thr98 residues in the DS-DSL domain interface of DDR2 are
critical for receptor interaction with collagen in vitro and re-
ceptor activation in cells. While wild-type DDR1 is not inhibited
by WRG-28, introducing these two residues into DDR1 was now
able to confer inhibition by WRG-28 compound.
WRG-28 Inhibition of DDR2 Blunts Tumor Cell Invasion, Migration, and
Tumor-Promoting Effects of CAFs. Genetic studies in vivo and cell-
based studies have shown that the action of DDR2 in breast
tumor cells and tumor stromal CAFs is critical for tumor in-
vasion, migration, and metastasis without affecting proliferation
(8, 9). Treatment of human BT549 and mouse 4T1 invasive
breast cancer cell lines (which express endogenous DDR2) with
Fig. 2. Computational prediction of WRG-28 binding site and directed mutagenesis. (A) Overall view of the DDR2 ECD structure depicting WRG-28 in a
putative binding site. (B) Detailed view of the predicted interactions of WRG-28. (C) Solid-phase binding assay of 25 nM recombinant DDR2-His or
DDR2F96A/T98A-His to the collagen peptide. (D) Size exclusion chromatography. Representative elution profile of DDR2-His or DDR2F96A/T98A-His on a Superdex
200 Increase 10/300 GL column is shown. (E) HEK293 cells transfected with DDR2-Myc or DDR2F96A/T98A-Myc were added to plates with indicated concen-
trations of collagen I for 4 h. Tagged proteins were immunoprecipitated with Myc antibody and bound products were Western blotted with pTyr 4G10 or Myc
antibodies. (F) HEK293 cells transfected with DDR1L96F/A98T -Myc were added to plates coated with 30 μg/mL collagen I for 4 h in the presence of indicated
concentrations of WRG-28. Tagged proteins were immunoprecipitated with Myc antibody and bound products were Western blotted with pTyr mAb
4G10 and reprobed with Myc antibodies. Representative blot is shown, quantification of three independent experiments represented as mean ± SEM.











WRG-28 inhibited their invasion/migration in 3D collagen I and
through matrigel to an extent comparable to cells RNAi-
depleted of DDR2 (Fig. 3 A and B and SI Appendix, Fig. S5 A,
C, and G). In both breast cancer cell lines, WRG-28 treatment
also inhibited DDR2-mediated SNAIL1 protein stabilization in
response to collagen stimulation (Fig. 3C and SI Appendix, Fig.
S5B). Treatment of BT549 cells with WRG-28 did not affect
their proliferation (SI Appendix, Fig. S5D).
The action of DDR2 in tumor stromal cells also plays an im-
portant role in regulation of metastasis (8). In particular, the ac-
tion of DDR2 in CAFs influences their tumor-promoting function,
in part, by mediating the secretion of paracrine signals that en-
hance collective invasiveness of tumor cells (8). To assess the
ability of WRG-28 to modulate such CAF effects, primary
MMTV-PyMT; Ddr2+/+; ROSA-LSL-TdTomato or MMTV-
PyMT; Ddr2−/−; ROSA-LSL-TdTomato primary tumor organo-
ids were isolated from breast tumors and plated in 3D collagen I
with mouse CAFs, derived from MMTV-PyMT; Ddr2+/+ or
MMTV-PyMT; Ddr2−/− breast tumors, in the presence or ab-
sence of WRG-28 and the number of invasive organoids scored
(SI Appendix, Fig. S6 A–E). Expression of Tomato was used to
confirm that invasive foci were composed of invading tumor cells
(Tomato positive) and not CAFs (Tomato negative) that had
migrated to the tumors (SI Appendix, Fig. S6F). Treatment of
Ddr2+/+ tumor organoids alone with WRG-28 reduced the
number of invasive tumor organoids to a level comparable to
that seen with Ddr2−/− tumor organoids (Fig. 3D). Addition of
Ddr2+/+ CAFs to Ddr2+/+ tumor organoids increased the number
of invasive organoids present, as expected (8) (Fig. 3D). WRG-
28 treatment potently reduced the number of invasive tumor
organoids, to a level equivalent to that observed when Ddr2−/−
breast tumor organoids and Ddr2−/− CAFs were cocultured (Fig.
3D). PI/annexin V staining confirmed that the reduction in in-
vasion was not due to toxic effects of WRG-28 (SI Appendix, Fig.
S6 G and H). These data indicated that not only did WRG-
28 inhibit primary tumor organoid invasion in 3D collagen I
matrices, but also the activity of DDR2 in CAFs to support in-
vasion of primary tumor organoids.
We were surprised that WRG-28 inhibited invasion of
BT549 and 4T1 breast cancer cells through Matrigel (Fig. 3B and
SI Appendix, Fig. S5 C and G) since Matrigel contains mostly
collagen IV, which is not a ligand for DDR2, and negligible
Fig. 3. WRG-28 treatment of tumor cells and CAFs. (A) Quantification of BT549 cell migration in 3D collagen I gels treated with 1 μM WRG-28 or control
compared with cells depleted of DDR2. Distance traveled relative to control cells was determined at 48 h (**P < 0.01, ANOVA, n = 4 per condition). See also SI
Appendix, Fig. S5A. (B) Quantification of Matrigel invasion of BT549 cell lines treated with 1 μM WRG-28 or control compared with cells shRNAi-depleted of
DDR2 or depleted cells rescued with kinase dead DDR2 (DDR2K608E) at 48 h. BT549 shSCR (blue), shDDR2 (green), or shDDR2 rescued with DDR2K608E (red).
Striped bars indicate WRG-28 treated cells (**P < 0.01, ANOVA, n = 3 inserts per condition). Experiment was performed three independent times with similar
results. See also SI Appendix, Fig. S5G. (C) BT549 cells added to collagen I-coated (2 mg/mL) or uncoated plates in the presence of WRG-28 (1 μM) or DMSO for
6 h. Western blots were performed with the indicated antibodies. Results were quantified by densitometric analysis of three independent experiments and
represented as mean ± SEM (**P < 0.01, n.s, not significant, ANOVA). (D) Quantification of invasive tumor organoids as a percent of total organoids scored
after 4 d. Thirty organoids per condition were scored. Data are mean ± SEM of a representative experiment of three independent experiments. n.s., not
significant, **P < 0.01 one-way ANOVA. (E) HEK293 cells transfected with DDR2T654I-Myc were added to plates coated with 30 μg/mL collagen I for 4 h in the
presence of various concentrations of WRG-28. DDR2 was immunoprecipitated with Myc antibody and bound products were Western blotted with pTyr
4G10 or DDR2 antibodies.
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amounts of fibrillar collagen (DDR2 ligand). DDR1 and DDR2
are known to be reciprocally expressed (41), and unlike DDR2,
DDR1 utilizes collagen IV as a ligand. We confirmed that neither
BT549 nor 4T1 cells express DDR1 at baseline. Importantly,
shRNA depletion of DDR2 or treatment with WRG-28 did not in-
duce expression of DDR1 in these cell lines (SI Appendix, Fig. S5E).
Various RTKs have been shown to display kinase-independent
functions within cells (42), therefore we asked if DDR2 exhibited
kinase-independent functions. To do so, we rescued DDR2 ex-
pression in shRNA-depleted BT549 cells with RNAi-resistant
kinase dead mutant (DDR2K608E) (SI Appendix, Fig. S5F).
DDR2K608E expression rescued the invasive potential of the tumor
cells through Matrigel (Fig. 3B). Importantly, treatment with
WRG-28 inhibited invasion of the DDR2K608E-expressing cells
(Fig. 3B and SI Appendix, Fig. S5G). In contrast, in 3D collagen I
invasion assays, DDR2K608E rescue did not restore invasiveness
(SI Appendix, Fig. S5H), indicating that the kinase-dependent
action of DDR2 predominates in this assay.
Another common setback to canonical TKIs is the development
of resistance mutations (20). Within the RTK family, gatekeeper
mutations are a common mode of resistance, and these have been
documented in DDR2 as well (21). In HEK293 cells expressing a
documented DDR2 gatekeeper mutation (DDR2T654I), WRG-
28 inhibited phosphorylation of the DDR2T654I mutant in re-
sponse to collagen I (Fig. 3E).
These data demonstrated that WRG-28, through its allosteric
action upon the ECD, was capable of inhibiting both kinase-
dependent and kinase-independent functions of DDR2. Addi-
tionally, WRG-28 maintained inhibitory action toward acquired
DDR2 mutations that are resistant to TKIs.
Validation of DDR2 as a Therapeutic Target To Prevent Breast Cancer
Metastasis. Ubiquitous deletion of Ddr2 in the MMTV-PyMT
mouse model of metastatic breast cancer significantly blunts
lung metastases (8). While these genetic studies establish the
importance of DDR2 in breast cancer metastasis, Ddr2 was de-
leted from birth or shortly thereafter in such models. The potential
to target DDR2 therapeutically after cancer developed and pre-
vent metastatic disease was still unknown. To test this possibility,
mice containing a conditional Ddr2fl/fl; ROSA-CreERT2; ROSA-
LSL-TdTomato; MMTV-PyMT and control Ddr2+/+; ROSA-
CreERT2; ROSA-LSL-TdTomato; MMTV-PyMT mice were
generated. These allow for temporal deletion of Ddr2fl/fl during
breast cancer progression upon treatment with tamoxifen.
In the MMTV-PyMT model, malignant transition occurs be-
tween 8 and 12 wk of age (43). Histologic examination of lungs at
this stage showed no evidence for metastases. At 8 wk of age,
mice were administered tamoxifen. Tomato fluorescence in tis-
sues was used to document Cre activity. In mice not treated with
tamoxifen, minimal tomato fluorescence was detected (SI Ap-
pendix, Fig. S7A). In mice treated with tamoxifen, the majority of
cells in the breast and lung showed Tomato fluorescence (SI
Appendix, Fig. S7A). In experimental mice, deletion of Ddr2 in
the tumor was confirmed by PCR (SI Appendix, Fig. S7B). In
experimental and control mice, there was no difference in la-
tency of primary tumor formation (Fig. 4A) or total primary
tumor burden per mouse (Fig. 4B). However, there was a sig-
nificant reduction in the number of lung metastases in mice
where Ddr2 was deleted during cancer progression (Fig. 4C and
SI Appendix, Fig. S7C). These data support the therapeutic tar-
geting of DDR2 in the setting of early stage breast cancer to
prevent metastasis.
WRG-28 Inhibits DDR2 Signaling in Vivo and Reduces Metastatic Lung
Colonization of Breast Tumor Cells. Since DDR2 signals sustain
tumor cell invasion/migration through the ECM by stabilizing
SNAIL1 protein level in breast tumor cells (9), we asked whether
SNAIL1 level in tumors could serve as a biomarker for WRG-
28 responses in vivo. 4T1 breast tumor cells that contain a
SNAIL1-clic beetle green (SNAIL1.CBG) bioluminescent fusion
protein that serves as a surrogate reporter of SNAIL1 protein
level in tumors were implanted into the breast of syngeneic mice.
After 1-cm tumors had formed, bioluminescence imaging was
conducted at baseline, and WRG-28 was administered by various
routes followed by bioluminescent detection of SNAIL1.CBG
levels (SI Appendix, Fig. S7D). Four hours after mice were given
a single i.v. administration of WRG-28 (10 mg/kg), compared
with control mice, WRG-28–treated mice exhibited a 60% reduc-
tion in SNAIL1.CBG level within the tumor (Fig. 5 A and B).
These data indicated that i.v. administration of WRG-28 attenuated
biochemical signaling of DDR2 in breast tumors in vivo.
To determine whether WRG-28 has the potential to inhibit
metastasis in vivo, DDR2-expressing 4T1 mouse breast tumor
cells expressing GFP/luciferase (4T1 GFP/luc) were injected into
syngeneic BALB/cJ mice via tail vein, and lung colonization and
growth were monitored by bioluminescence imaging and con-
firmed histologically. Genetic RNAi depletion of DDR2 in
4T1 cells significantly reduced lung metastatic colonization (Fig.
5 C and D and SI Appendix, Fig. S7F). i.v. administration of
WRG-28 at 10 mg/kg daily for 7 d was chosen for dosing based
on the results of SNAIL.CBG modulation by the compound (SI
Appendix, Fig. S7D). WRG-28 reduced lung colonization to a
level comparable to shDDR2-depleted cells (Fig. 5 C and D and
SI Appendix, Fig. S7F). Histologic analysis of GFP+ tumors in the
lungs isolated at termination (7 d) confirmed the bioluminescent
results (Fig. 5E and SI Appendix, Fig. S7 E and G).
A related compound, cinnabarinic acid, which is inactive as a
DDR2 inhibitor in vitro (Fig. 1A), was also tested in this model
and demonstrated no effect on lung colonization, further sup-
porting the notion that the results of WRG-28 treatment are due
to its inhibitory activity toward DDR2 (SI Appendix, Fig. S7H).
While stromal DDR2 plays a critical role in the primary site in
promoting the invasiveness of tumor cells (8), the role of stromal
Fig. 4. Genetic validation of DDR2 as a therapeutic target. (A) Primary tu-
mor growth rates of indicated mice (Ddr2 deleted at 8 wk) determined by
the age at which the largest tumor reached 2 cm in diameter. n = 10–26 per
group. Data are presented as mean ± SEM. (B) Total primary tumor burden
of indicated mice (Ddr2 deleted at 8 wk) was determined by the sum of the
weight of all tumors for each mouse when the largest tumor reached 2 cm in
diameter. n = 10–26 per group. Data are presented as mean ± SEM. (C)
Quantification of lung metastases in indicated mice (Ddr2 deleted at 8 wk)
was calculated by the number of microscopically visible metastases from
three H&E-stained sections of lung taken >200 μm apart and normalized to
total lung area. *P < 0.05, two tailed unpaired t test; n = 10–26 mice per
group. Data are presented as mean ± SEM.











DDR2 in the metastatic niche does not contribute to the lung
colonization by breast tumor cells in this model (SI Appendix,
Fig. S7I). This is consistent with the observation that treatment
with WRG-28 in this assay does not confer any additional benefit
beyond what is seen when shDDR2-depleted breast tumor cells
are allowed to colonize. These data indicated that WRG-28 had
the potential to inhibit colonization of the lung by metastatic
breast tumor cells in vivo.
Discussion
We have identified a potent and selective small molecule in-
hibitor of DDR2. In contrast to other inhibitors, WRG-28 acts
via the ECD of the receptor in an allosteric manner, potentially
disrupting receptor clustering. In support of the proposed allo-
steric mode of action, WRG-28 is not a strong orthosteric in-
hibitor of ligand binding, is highly selective, dissociated preformed
DDR2–collagen complexes, disrupted receptor clustering in so-
lution, inhibited kinase-independent receptor function, and
inhibited mutant DDR2 receptors resistant to traditional TKIs.
Computational modeling followed by mutagenesis analysis
suggests a region at the interface of the extracellular DS and
DSL domains as the putative binding site of WRG-28. In the
absence of structural data, we cannot definitively confirm the
predicted binding site. However, when key residues within this
site are mutated (DDR2F96A/T98A), collagen binding and DDR2
activation are abrogated, and when these residues in DDR2
(F96 and T98) were substituted into DDR1, sensitivity of
DDR1 to inhibition by WRG-28 was conferred. Since WRG-
28 may interfere with receptor clustering, it is possible that the
binding site could be a composite site formed by two or more
interacting protomers. We cannot exclude contributions from
the short extracellular juxtamembrane region as it is absent from
the current model.
Previous studies have suggested that receptor clustering is
critical for DDR2 binding to collagen (31), and DDR1 clustering
enhances activation and strengthens DDR1 binding to collagen
(44, 45). If DDR2 oligomerization is required for efficient col-
lagen binding and receptor activation, the inability of the
DDR2F96A/T98A mutant to form higher order clusters would
provide a straightforward explanation for its lack of binding and
activation. We cannot exclude the possiblility that this region
could function allosterically to regulate the collagen ligand
binding site from a distance as have been described for integrins
and other receptors (46). Alternatively, if residues within the DS-
DSL domain interface region act to position two DDR2 proto-
mers for binding and subsequent activation, these residues might
contribute to conformational changes necessary for ligand binding
and receptor activation.
To our knowledge, there is only one other example of a small
molecule allosterically targeting the ECD of an RTK (FGFR)
(22, 23). That compound inhibits signaling linked to receptor in-
ternalization in an allosteric manner without affecting orthosteric
ligand binding. Although nonclassical small molecule inhibitors
that disrupt protein complexes or multimerization of receptors
have been reported (47, 48), to our knowledge no such inhibitors
have been identified for any RTK. These types of nonclassical or
allosteric inhibitors remain an elusive goal for drug development
as they offer a number of favorable therapeutic attributes, such as
increased selectivity and safety (24, 25). Indeed, neither the ho-
mologous family member DDR1 nor the unrelated collagen re-
ceptor α1β1 integrin is inhibited by WRG-28.
Since WRG-28 has the potential to disrupt preformed re-
ceptor complexes, this may be important for its in vivo efficacy,
where the ligand (fibrillar collagen) is in great excess. WRG-
28 binding to DDR2–collagen complexes appears to accelerate
the intrinsically slow dissociation of the complex. Extrapolation
of this in vitro data would suggest that in vivo the DDR2–col-
lagen interaction equilibrium lies strongly in favor of receptor–
ligand complex. Therefore, this mode of inhibition may be
poised as advantageous over blockage of ligand binding with an
orthosteric inhibitor, where an empty receptor would be needed
for drug binding.
GEMMs (8) and correlative human studies (49, 50) have
shown that DDR2 is important for metastasis of breast cancer
through its function in both tumor cells, as well as CAFs.
Therefore, DDR2 inhibition can target both the invasive tumor
cell as well as stromal cells concurrently. DDR2 activation has
also been implicated in other cancer types (51) as well as other
disease states such as osteoarthritis (52) and cardiac (53) and
pulmonary (54) fibrosis. It will be important to determine
whether DDR2 inhibition with WRG-28 or derivatives would be
a useful therapeutic strategy in those settings. In the context of
cancer, it is important to note that genetic depletion of Ddr2 or
selective pharmacologic inhibition of the receptor does not affect
primary tumor growth (8). Thus, in humans, treatment with such
an antimetastasis agent would likely need to be administered as
an adjuvant therapy along with standard chemotherapeutic
agents that reduce tumor cell growth.
Materials and Methods
Solid-Phase Collagen-Binding Experiments. Collagens or collagen peptides
were diluted in 0.01 M acetic acid coated onto Immulon 2 HB 96-well plates
(Fisher Scientific) overnight at 4 °C. Wells were then blocked for 1 h at room
temperature with 1 mg/mL BSA in PBS plus 0.05% Tween 20. Recombinant
proteins, diluted in incubation buffer (0.5 mg/mL BSA in PBS plus 0.05%


































































































































Fig. 5. WRG-28 prevention of lung colonization by metastatic breast tumor
cells. (A) Representative bioluminescent images of 4T1-Snail-CBG tumor-
bearing mice at 4 h following treatment with WRG-28 or saline control
compared with pretreatment baseline. (B) Quantification of relative bio-
luminescence compared with pretreatment baseline. Mean ± SEM, *P < 0.05
(n = 3 controls, n = 8 treatment group). (C) BALB/cJ mice are injected by tail
vein with 5 × 105 4T1-GFP-luc expressing cells and lungs evaluated for the
presence of metastatic tumors: control (shSCR), DDR2 depleted (shDDR2),
and mice injected with control cells and treated daily with WRG-28, control
(blue circles); WRG-28 treated (green triangles); and shDDR2 depleted (red
squares). Mean ± SEM; data derived from one experiment of five mice per
condition. **P < 0.01 two-way ANOVA. See also SI Appendix, Fig. S7F. (D)
Representative bioluminescent images of mice quantified in C following
initial injection of cells and after 7 d for each experimental group. (E)
Quantification of percentage of GFP-tumor positive area per lung at end-
point. Two sections through each of five lobes per animal quantified. Data
derived from two experiments, n = 9 mice for each condition. Mean ± SEM,
**P < 0.001, one-way ANOVA. See also SI Appendix, Fig. S7E.
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Tween 20), were added for 3 h at room temperature. Wells were washed
with incubation buffer between all incubation steps. Bound DDR2-His pro-
tein or α1β1-His were detected with anti-His–conjugated HRP monoclonal
antibody (1:2,500 dilution), added for 1 h at room temperature. Bound
DDR1-FC or DS2-Fc protein were detected with goat anti-human Fc coupled
to horseradish peroxidase (1:2,500 dilution), added for 1 h at room tem-
perature. Detection was achieved using o-phenylenediamine dihydro-
chloride (Sigma), added for 3–5 min. The reaction was stopped with 3 M
H2SO4, and plates were read in a 96-well plate reader at 492 nm.
Size Exclusion Chromatography. Size exclusion chromatographywas carried out
at 4 °C using a BioRad Biologic Duoflow system equipped with a Superdex 200
Increase 10/300 GL column (GE). Experiments were run using PBS at a 0.5 mL/min
flow rate, and elution was monitored at UV absorbance 280 nm. Twenty-
five micrograms of protein were incubated in solution with 1 μMWRG-28 or
DMSO for 1 h, then injected, and 1-mL fractions were collected upon elution.
Fractions were concentrated using Vivaspin 500 centrifugal concentrators
(10,000 molecular weight cutoff) and run on 10% gel under nonreducing
conditions. To assess collagen binding of various fractions, they were imme-
diately spin concentrated, protein concentration determined, and normalized
across samples. Samples were then subjected to binding in the solid-phase
plate assay.
Migration and Invasion Assays. For 3D cell migration assays, 105 cells were
embedded in 20 μL of type I collagen gel (2.0 mg/mL) extracted from rat tail
(BD Biosciences). After gelling, the plug was embedded in a cell-free collagen
gel (2.0 mg/mL) within a 24-well plate. After allowing the surrounding colla-
gen matrix to gel (1 h at 37 °C), 0.5 mL of culture medium was added on the
top of the gel and cultured for another 2 d. Invasion distance from the inner
collagen plug into the outer collagen gel was quantified. For invasion assays,
Transwell cell invasion assays were performed using either 24-well poly-
carbonate membrane (Corning) with 8-μm pore size, or 24-well FluoroBlok
Transwell insert (BD) with 8-μm pore size. Inserts were prepared by coating the
upper surface with 1 mg/mL Matrigel (BD Biosciences) for 4–6 h at 37 °C in a
5% CO2 incubator. BT549 or 4T1 cells (5 × 10
4) in DMEM containing 1% FBS
were seeded into the upper chamber of the insert. The bottom chamber
contained DMEMwith 10% FBS. After 24 or 48 h, membranes were processed.
Polycarbonate membranes were stained with HEMA3 staining kit (Fisher) and
then mounted and enumerated based on number of cells per 20× high power
field, five fields per insert. For FluoroBlok transwells, luminescence intensity
was measured using a FluoStar Optima microplate reader (BMG Labtech) for
10 individual fields on the bottom of each insert.
Tumor Organoid and CAF Coculture. Primary tumor organoids (30–50, each 200–
1,000 cells) with or without CAFs (750 cells) were cultured in 50-μL droplets of
3 mg/mL acid-solubilized rat tail collagen I (BD Biosciences), and the number of
invasive organoids were enumerated daily for 4 d. Organoids were scored as
invasive if they contained ≥1 protrusive projection.
Animal Studies. All procedures and care of animals were done in accordance
with a protocol approved by the Washington University Institutional Animal
Care and Use Committee (St. Louis, MO) and were performed in accordance
with institutional and national guidelines.
Temporal Deletion of Ddr2. Ddr2fl/fl; ROSA-LSL-TdTomato or Ddr2+/+; ROSA-
LSL-TdTomato mice were crossed to MMTV-PyMT; ROSA-CreERT2 mice. At
8 wk, experimental and control mice were switched to 400 citrate
tamoxifen-supplemented nonpelleted dry feed (Envigo) for 2 wk. Tumor-
bearing mice were monitored weekly and euthanized when the largest tu-
mor reached 2 cm in diameter. Lungs were fixed overnight in 10% formalin,
cryopreserved in 30% sucrose overnight, and finally embedded in OCT and
frozen in a dry ice/ethanol bath. Frozen specimens were sectioned with a
cryostat (6 μm) and analyzed by fluorescence microscopy for tomato ex-
pression or stained with hematoxylin/eosin (H&E) for histological analysis.
For analysis of lung metastasis, microscopically visible metastatic foci were
counted from three H&E-stained sections taken 200 μm apart and reported
as the total number of metastases in those three sections.
In Vivo Breast Implant Assay. Eight-week-old female BALB/cJ mice (Jackson
Labs) were anesthetized. A small Y-shaped incision was made in the lower
abdominal skin to expose the fourth mammary gland. 4T1-Snail.CBG cells (1 ×
106) in 50 μL of DMEM were injected into the fourth mammary gland using a
29-gauge needle. The skin flaps were replaced and closed. When tumors
were 1 cm in diameter, in vivo biochemical response studies were conduced
by BLI at baseline, followed by i.v. lateral tail vein injection of either control
saline, or indicated doses of WRG-28 in saline/DMSO, and BLI at indicated
time points. The baseline BLI signal for each mouse served as its own control.
For lung metastasis formation assay, 5 × 105 cells in 100 μL of DMEM were
injected into the lateral tail vein of BALB/cJ mice. Beginning on day 0, mice
were treated with either control saline or 10 mg/kg WRG-28 in saline/DMSO
daily for 7 d, and BLI imaging was used to follow tumor growth at time
points indicated. After 7 d, mice were euthanized, and lungs were removed
and fixed in 10% formalin for 24 h, cryopreserved in 30% sucrose overnight,
and finally embedded in OCT and frozen in a dry ice/ethanol bath. Frozen
specimens were sectioned with a cryostat (6 μm) and analyzed by fluores-
cence microscopy for GFP expression or stained with H&E for histological
analysis.
To test the contribution of stromal DDR2 in the lung colonization assay,
global deletion of DDR2 in C57BL/6 mice was achieved by backcrossing the
DDR2-null allele in C57BL/6 mice for 10 generations. Heterozygote crosses
generated DDR2+/+ (wild-type) and DDR2−/− (null) mice for the experiment.
Bo1-GFP-luc cells, a C57BL/6-derived mouse breast tumor line that is known
to metastasize to lung, were injected into the lateral tail vein (5 × 105 cells in
100 μL of DMEM), and BLI imaging was used to follow tumor growth at the
time points indicated.
For all BLI, mice were anesthetized with isoflurane and imaged using the
IVIS 100 bioluminescent imaging system (PerkinElmer) following an i.p. in-
jection of D-luciferin (150 mg/kg).
Extended methods can be found in the SI Appendix.
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